During inflammation or immune surveillance, leukocytes in the blood pass through endothelial cells lining the luminal site of blood vessels and then migrate to the underlying tissue. The process is called leukocyte transendothelial migration (TEM). Leukocyte transendothelial migration occurs across micron-wide gaps in the specific post-capilary venules produced by the transmigrating leukocyte.
Leukocyte transendothelial migration is indispensable to initial the innate or adaptive immune response. In other words, leukocyte migration from the blood into tissues is vital for immune surveillance and inflammation. The inflammatory response is the body's defense mechanism against bacterial infection, cell damage, foreign irritants, and other adverse factors.
When the inflammatory reaction occurs, endothelial cells attract and direct leukocytes (or other immune cells) to move across the vascular endothelial cell membrane to the inflammatory site, where leukocytes exert their physiological functions.
Leukocyte transendothelial migration is a complex and multi-step process. It is the result of interaction between receptors expressed on leukocytes and ligands on endothelial cells. Endothelial cells contain a dense cytoskeletal network, so leukocyte transmigration must overcome these mechanical barriers as leukocytes squeeze their nuclei through endothelial gaps and pores. Recent findings suggest that endothelial cells are not a passive barrier. And upon engagement by transmigrating leukocytes trigger extensive dynamic modifications of the endothelial actin cytoskeleton. The whole process includes the rolling of leukocytes, leukocyte activation ＆ arrest/adhesion, and transendothelial migration.
Various inflammatory factors and adhesion molecules are involved in the process of leukocyte transendothelial migration. They control the morphology and movement of leukocytes and endothelial cells by regulating the dynamic recombination of the cytoskeleton in endothelial cells to realize the leukocyte transendothelial migration.
The systemic circulation of leukocytes through the veins slows down or pulls over initiates migration of white blood cells during inflammation. The edge phenomenon refers to the movement of leukocytes in the bloodstream of the venules near the endothelial surface of the vessels.
Selectins mediate leukocyte capture into the vessel wall. L-selectin is structurally expressed on leukocytes, which facilitates the binding of leukocytes in the flowing bloodstream with L- selectin ligands on vascular endothelial cells to catch leukocytes. Leukocytes adhere through L-selectin to cellular adhesion molecules (CAM) or glycoproteins such as CD34 on the endothelial cells. L-selectin induces CXCR4 upregulation from intracellular granules on the leukocyte surface, resulting in increased activation of Rap1. Rap1 induces α4-integrin activation. Adhered leukocytes move forward by leading-edge protrusion and retraction of its tail. The rolling of leukocytes along the endothelia gives them prolonged contact with endothelial cells, allowing them to make effective contact on the surface of endothelial cells.
Leukocytes use mainly β1 integrin (VLA-4/α4β1) and β2 (LFA-1/αLβ2) integrin to firmly adhere to the endothelium. The ligands for these integrins on the endothelium are respectively VCAM-1 (vascular cell adhesion molecule-1) and ICAM-1 (intercellular cell adhesion molecule-1).
The β1/β2 integrin activates leukocytes and allows them to adhere more firmly to the endothelial surface. Activated endothelial cells produce chemokines such as IL-8 and PAF. IL-8 is one of the major endogenous chemokines that activate neutrophils, causing a series of changes between cells that eventually lead to cell migration.
The formation and depolymerization of focal adhesion play an important role in the migration of leukocytes across the endothelium. The small GTPase Rac1 induces ruffles, possibly leading to docking structures and ROS production. ROS suppresses phosphatase activity, which causes increased kinase activity and loss of VE-cadherin- mediated cell-cell junctions. The small GTPase RhoA subsequently induces activation of MLC and cell contraction. All these processes, together with junctional molecules such as PECAM-1, JAM, and CD99, are likely to promote the transmigration of leukocytes across an endothelial monolayer.
|MYLPF||MYLPF Antibody||MYLPF Protein||MYLPF cDNA||MYLPF ELISA Kit|
|NCF1||NCF1 Antibody||NCF1 Protein||NCF1 cDNA||NCF1 ELISA Kit|
|NCF2||NCF2 Antibody||NCF2 Protein||NCF2 cDNA||NCF2 ELISA Kit|
|NCF4||NCF4 Antibody||NCF4 Protein||NCF4 cDNA||NCF4 ELISA Kit|
|OCLN||OCLN Antibody||OCLN Protein||OCLN cDNA||OCLN ELISA Kit|
|PECAM1||PECAM1 Antibody||PECAM1 Protein||PECAM1 cDNA||PECAM1 ELISA Kit|
|PIK3CB||PIK3CB Antibody||PIK3CB Protein||PIK3CB cDNA||PIK3CB ELISA Kit|
|PIK3R2||PIK3R2 Antibody||PIK3R2 Protein||PIK3R2 cDNA||PIK3R2 ELISA Kit|
|PLCG1||PLCG1 Antibody||PLCG1 Protein||PLCG1 cDNA||PLCG1 ELISA Kit|
|PLCG2||PLCG2 Antibody||PLCG2 Protein||PLCG2 cDNA||PLCG2 ELISA Kit|
|PRKCA||PRKCA Antibody||PRKCA Protein||PRKCA cDNA||PRKCA ELISA Kit|
|PRKCB||PRKCB Antibody||PRKCB Protein||PRKCB cDNA||PRKCB ELISA Kit|
|PRKCG||PRKCG Antibody||PRKCG Protein||PRKCG cDNA||PRKCG ELISA Kit|
|PTK2||PTK2 Antibody||PTK2 Protein||PTK2 cDNA||PTK2 ELISA Kit|
|PTK2B||PTK2B Antibody||PTK2B Protein||PTK2B cDNA||PTK2B ELISA Kit|
|PTPN11||PTPN11 Antibody||PTPN11 Protein||PTPN11 cDNA||PTPN11 ELISA Kit|
|PXN||PXN Antibody||PXN Protein||PXN cDNA||PXN ELISA Kit|
|RAC1||RAC1 Antibody||RAC1 Protein||RAC1 cDNA||RAC1 ELISA Kit|
|RAC2||RAC2 Antibody||RAC2 Protein||RAC2 cDNA||RAC2 ELISA Kit|
|RAP1A||RAP1A Antibody||RAP1A Protein||RAP1A cDNA||RAP1A ELISA Kit|